S Sirakov1, A Sirakov2, P Bhogal3, M Penkov2, K Minkin4, K Ninov4, H Hristov4, V Karakostov4, R Raychev5. 1. Radiology department, University Hospital St. Ivan Rilski, Sofia, Bulgaria. ssirakov@bsunivers.com. 2. Radiology department, University Hospital St. Ivan Rilski, Sofia, Bulgaria. 3. Department of Interventional Neuroradiology, The Royal London Hospital, London, UK. 4. Neurosurgery department, University Hospital St. Ivan Rilski, Sofia, Bulgaria. 5. Department of Neurology and Comprehensive Stroke Center, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.
Abstract
BACKGROUND AND PURPOSE: The p64 is a flow modulation device designed to be used in endovascular treatment of intracranial aneurysms. There is limited data on the long-term effectiveness of the device. This study sought to determine the safety and long-term efficacy of this device. METHODS: A retrospective review of a prospectively maintained database was performed to identify all patients treated with a p64 between March 2015 and November 2018 at University Hospital St. Ivan Rilski. Anatomical features, intraprocedural complications, clinical, and angiographic outcomes were also taken into account and reviewed. RESULTS: A total of 72 patients with 72 aneurysms who met the inclusion criteria were identified. Device placement was successful in all patients. Follow-up angiographic imaging at 6 months showed complete occlusion (O'Kelly-Marotta scale [OKM] D) in 55 (76.3%) patients, subtotal aneurysmal filling (OKM B) in 10 (13.8%) patients, and neck remnant (OKM C) in 7 (9.7%) patients. Catheter angiography at 12 months was available for 70 patients (97.2%) and of these patients 91.4% of the aneurysms were completely occluded (OKM D) (64/72). Delayed angiography at 24 months was available for 68 patients (94.4%) and of these 98.5% (67/68) had completely occluded aneurysms. A 36-month angiography was available for 61 patients (84.4%) by which point all aneurysms had been completely occluded (100%). Permanent morbidity due to delayed aneurysmal rupture occurred in one patient (1.38%). The mortality rate was 0%. Self-limiting mild intimal hyperplasia was seen in 2 patients (2.72%). CONCLUSION: Treatment of intracranial aneurysms with a p64 flow modulation device is safe and effective with a high success rate and only infrequent complications.
BACKGROUND AND PURPOSE: The p64 is a flow modulation device designed to be used in endovascular treatment of intracranial aneurysms. There is limited data on the long-term effectiveness of the device. This study sought to determine the safety and long-term efficacy of this device. METHODS: A retrospective review of a prospectively maintained database was performed to identify all patients treated with a p64 between March 2015 and November 2018 at University Hospital St. Ivan Rilski. Anatomical features, intraprocedural complications, clinical, and angiographic outcomes were also taken into account and reviewed. RESULTS: A total of 72 patients with 72 aneurysms who met the inclusion criteria were identified. Device placement was successful in all patients. Follow-up angiographic imaging at 6 months showed complete occlusion (O'Kelly-Marotta scale [OKM] D) in 55 (76.3%) patients, subtotal aneurysmal filling (OKM B) in 10 (13.8%) patients, and neck remnant (OKM C) in 7 (9.7%) patients. Catheter angiography at 12 months was available for 70 patients (97.2%) and of these patients 91.4% of the aneurysms were completely occluded (OKM D) (64/72). Delayed angiography at 24 months was available for 68 patients (94.4%) and of these 98.5% (67/68) had completely occluded aneurysms. A 36-month angiography was available for 61 patients (84.4%) by which point all aneurysms had been completely occluded (100%). Permanent morbidity due to delayed aneurysmal rupture occurred in one patient (1.38%). The mortality rate was 0%. Self-limiting mild intimal hyperplasia was seen in 2 patients (2.72%). CONCLUSION: Treatment of intracranial aneurysms with a p64 flow modulation device is safe and effective with a high success rate and only infrequent complications.
Authors: Marta Aguilar Pérez; Elina Henkes; Victoria Hellstern; Carmen Serna Candel; Christina Wendl; Hansjörg Bäzner; Oliver Ganslandt; Hans Henkes Journal: Oper Neurosurg (Hagerstown) Date: 2021-03-15 Impact factor: 2.703
Authors: Alain Bonafe; Marta Aguilar Perez; Hans Henkes; Pedro Lylyk; Carlos Bleise; Gregory Gascou; Stanimir Sirakov; Alexander Sirakov; Luc Stockx; Francis Turjman; Andrey Petrov; Christian Roth; Ana-Paula Narata; Xavier Barreau; Christian Loehr; Ansgar Berlis; Laurent Pierot; Marcin Miś; Tony Goddard; Andy Clifton; Joachim Klisch; Cezary Wałęsa; Massimo Dall'Olio; Laurent Spelle; Frédéric Clarencon; Sergey Yakovlev; Peter Keston; Nunzio Paolo Nuzzi; Stefanita Dima; Christina Wendl; Tine Willems; Peter Schramm Journal: J Neurointerv Surg Date: 2021-11-15 Impact factor: 8.572
Authors: C Zaeske; T Hickethier; J Borggrefe; L Goertz; R Dettmeyer; M Schlamann; N Abdullayev; C Kabbasch Journal: AJNR Am J Neuroradiol Date: 2020-12-31 Impact factor: 3.825
Authors: Jens Maybaum; Hans Henkes; Marta Aguilar-Pérez; Victoria Hellstern; Georg Alexander Gihr; Wolfgang Härtig; André Reisberg; Dirk Mucha; Marie-Sophie Schüngel; Richard Brill; Ulf Quäschling; Karl-Titus Hoffmann; Stefan Schob Journal: Front Neurol Date: 2021-07-01 Impact factor: 4.003
Authors: Victoria Hellstern; Marta Aguilar-Pérez; Elina Henkes; Carmen Serna-Candel; Christina Wendl; Hansjörg Bäzner; Oliver Ganslandt; Hans Henkes Journal: Front Neurol Date: 2021-07-16 Impact factor: 4.003